secwatch.observer — SEC 8-K summary
======================================

Issuer:     WEST PHARMACEUTICAL SERVICES INC (WST)
CIK:        0000105770
Form:       8-K
Filed at:   2022-04-01T23:59:59+00:00
Accession:  0000105770-22-000010
Event type: debt
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

West Pharma amends credit facility to $500M, extends to 2027; adds Japanese subsidiary as borrower
--------------------------------------------------------------------------------

- Increased credit facility from $300M to $500M senior unsecured revolving; maturity extended to March 31, 2027.
- Added West Pharmaceutical Services Holding Japan Godo Kaisha as additional borrower under the facility.
- Interest: Term SOFR + 0.10% + margin of 87.5-137.5 bps or base rate + 0-37.5 bps.
- Financial covenant: Net Consolidated Debt to modified EBITDA ratio max 3.5:1 (4.0:1 for qualified acquisitions up to 4 quarters).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/105770/000010577022000010/0000105770-22-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/105770/000010577022000010/wst-20220331.htm
  HTML page:      https://secwatch.observer/filing/0000105770-22-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer